Evidence map›Paper›PMID 40492166›Full record

ArticleRespiratory medicine case reports2025

Compassionate use of tezepelumab in near fatal asthma: A case report and review of the literature.

Mako Nakajima, Masashi Matsuyama, Yuki Yamazaki, Hiroya Sunabe, Yuta Takahashi, Keishun Boku, Takeshi Miura, Tomohiro Tamura, Yoshiaki Inoue, Nobuyuki Hizawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Asthma and corticosteroids "Frontiers in allergy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mako NakajimaDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Masashi MatsuyamaDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Yuki YamazakiDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Hiroya SunabeDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Yuta TakahashiDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Keishun BokuDepartment of Emergency and Critical Care Medicine, University of Tsukuba, Ibaraki, Japan.
Takeshi MiuraDepartment of Emergency and Critical Care Medicine, University of Tsukuba, Ibaraki, Japan.
Tomohiro TamuraRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Yoshiaki InoueDepartment of Emergency and Critical Care Medicine, University of Tsukuba, Ibaraki, Japan.
Nobuyuki HizawaDepartment of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 38-year-old man with near fatal asthma requiring intubation and invasive mechanical ventilation (IMV) was transferred to our hospital. Veno-venous extracorporeal membrane oxygenation (VV-ECMO) was initiated due to hypotension and mediastinal emphysema secondary to barotrauma. Since high-dose systemic corticosteroid therapy failed to relieve the severe bronchospasm, a single dose of tezepelumab was administered on a compassionate basis. This intervention resulted in successful extubation 7 days later. This is a rare case in which a biologic agent was used as a rescue therapy for near fatal asthma. This case is presented along with a review of the relevant literature.

Indexed as

BiologicsNear fatal asthmaTezepelumabVeno-venous extracorporeal membrane oxygenation (VV-ECMO)

Identifiers

PMID40492166
PMCPMC12147447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.